Format

Send to

Choose Destination
Pancreas. 2014 Nov;43(8):1303-5. doi: 10.1097/MPA.0000000000000174.

Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.

Author information

1
From the Departments of *Oncology and †Nursing, King Hussein Cancer Center, Amman, Jordan.

Abstract

OBJECTIVES:

Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan.

METHODS:

A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles.

RESULTS:

Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths.

CONCLUSIONS:

Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.

PMID:
25036906
DOI:
10.1097/MPA.0000000000000174
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center